{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "VIRACTA THERAP.I.DL-,0001", "longName": "Viracta Therapeutics, Inc.", "messageBoardId": "finmb_38720301", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 1.9607825, "regularMarketPrice": 1.04, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.81592923, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 5.65, "earningsTimestamp": 1683576300, "earningsTimestampStart": 1691409600, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.19, "epsForward": -1.31, "epsCurrentYear": -3.54, "priceEpsCurrentYear": -0.2937853, "sharesOutstanding": 38410900, "bookValue": 1.451, "fiftyDayAverage": 1.3594, "fiftyDayAverageChange": -0.31940007, "fiftyDayAverageChangePercent": -0.23495665, "twoHundredDayAverage": 2.61845, "twoHundredDayAverageChange": -1.57845, "twoHundredDayAverageChangePercent": -0.6028185, "marketCap": 39947336, "forwardPE": -0.79389316, "priceToBook": 0.71674705, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": 0.01999998, "regularMarketTime": 1683872402, "regularMarketDayHigh": 1.04, "regularMarketDayRange": "1.04 - 1.04", "regularMarketDayLow": 1.04, "regularMarketVolume": 50, "regularMarketPreviousClose": 1.02, "bid": 1.06, "ask": 1.08, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.04, "averageDailyVolume3Month": 3, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.23999995, "fiftyTwoWeekLowChangePercent": 0.29999992, "fiftyTwoWeekRange": "0.8 - 5.65", "fiftyTwoWeekHighChange": -4.61, "firstTradeDateMilliseconds": 1614668400000, "symbol": "RYI.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "2533 South Coast Highway 101", "address2": "Suite 210", "city": "Cardiff-by-the-Sea", "state": "CA", "zip": "92007", "country": "United States", "phone": "858 400 8470", "website": "https://www.viracta.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 2021. The company was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Andrew Rothera", "age": 59, "title": "CEO, Pres & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 365032, "fmt": "365.03k", "longFmt": "365,032"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel R. Chevallard CPA", "age": 42, "title": "CFO, COO, Treasurer & Sec.", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 647909, "fmt": "647.91k", "longFmt": "647,909"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 37032, "fmt": "37.03k", "longFmt": "37,032"}}, {"maxAge": 1, "name": "Dr. Susan  Perrine M.D.", "title": "Scientific Founder and Consultant", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ronald J. Berenson M.D.", "age": 70, "title": "Co-Founder and Consultant", "yearBorn": 1952, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. George  Hillman", "title": "Co-Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Thalia  Papayannopoulou M.D.", "title": "Co-Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Robert M. Williams Ph.D.", "age": 67, "title": "Co-Founder", "yearBorn": 1955, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Douglas V. Faller M.D., Ph.D.", "title": "Scientific Founder & Chairman of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ayman  El-Guindy", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Stewart M. Brown", "title": "Sr. VP of Legal Affairs & Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}